Dr Chris Quirk
Christopher Quirk graduated from the University of Western Australia and trained in dermatology at public hospitals in Western Australia with regular visits to clinics in the eastern states, Europe and the USA.
He currently works in private practice at Dermatology Specialist Group in Ardross and at St John of God Dermatology in Subiaco. He was previously Head of Department of Dermatology at Royal Perth Hospital.
He has previously served as a director of two listed ASX biotech companies and has served on advisory boards for numerous pharmaceutical companies: Novartis, Roche, Merck Sharp & Dohme, Allergan, Pfizer, Wyeth, Abbott, Glaxo Smith Kline, Janssen, Galderma, Eli Lilly.
He has published papers on malignant melanoma, Grover’s Disease, Transdermal drug delivery and basal cell carcinoma.
In 2000, he was a founder panel member of the now Western Australian Kirkbride melanoma advisory service at the Harry Perkins Institute of Medical Research.
In addition to in-person patient assessments, he consults on most days with rural and isolated patients across Australia via telehealth.